The Bank of Cyprus Oncology Centre (BOCOC, Nicosia, Cyprus) has acquired two Elekta Synergy systems and an Elekta Synergy Platform for the non-invasive treatment of cancer.
The systems will be delivered throughout 2009, with the first installation expected to begin in March 2009. The acquisition was made with the help of a donation from the Bank of Cyprus Medical FoundationThe first Elekta Synergy system will be installed into a newly-built bunker providing the hospital, for the first time, with capabilities such as whole-body Image Guided Radiotherapy (IGRT), Stereotactic Radiotherapy (SRT) with a suite of specialized stereotactic accessories, and Intensity Modulated Radiotherapy (IMRT) using Volumetric Modulated Arc Therapy (VMAT) technology. Second and third Elekta linear accelerators will be installed into existing bunkers replacing two Siemens linear accelerators. 'We have high expectations from our new collaboration with Elekta,' said Dr Chris Constantinou, director of medical physics at the BOCOC. 'Key factors for our decision included our positive evaluation of Elekta's fully-digital architecture enabling use of remote service functionality through Intellimax, the performance of XVI for advanced IGRT applications, the offered comprehensive set of equipment for Stereotactic Radiotherapy and Radiosurgery applications and not least VMAT which promises to significantly improve both the quality and throughput of our patients' treatments.' The centre will also upgrade their existing oncology information system to Elekta's comprehensive oncology charting solution, Mosaiq from Impac Software. 'We considered Mosaiq to be a natural successor to our existing Lantis network and we were impressed by Elekta's professional appreciation of and commitment to our need to maintain and seamlessly upgrade our existing patient database,' Dr Constantinou added. Dr Demetris Andreopoulos, director of radiation oncology of the BOCOC, further commented, 'The Bank of Cyprus Oncology Center in Nicosia services the needs for cancer treatment for the entire Cypriot population of just under one million people. Our decision in favour of Elekta therefore followed a very careful evaluation of all the factors that would maximize both the clinical efficacy and quality of the services we offer. We felt that with its offered package Elekta addressed successfully these key factors and we look forward to a positive and fruitful collaboration with them as our new partners for the benefit of all the patients we treat.'
|
